{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:55:13Z","timestamp":1790625313997,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatic veno-occlusive disease (VOD) is an endothelial injury seen after stem cell transplantation that can also occur with conventional chemotherapies. Morbidity can be significant, highlighting the need for effective supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report:<\/jats:title>\n                    <jats:p>We present a pediatric patient with Wilms tumor who developed VOD after dactinomycin and vincristine. Management included a molecular adsorbent recirculating system (MARS) for acute liver failure and irinotecan with vincristine (VI) as bridging chemotherapy before gradual reintroduction of dactinomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The patient remains in remission without long-term VOD complications. MARS facilitated hepatic recovery, and disease control was maintained with VI serving as a low-hepatotoxic bridging regimen before rechallenging with dactinomycin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003253","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:01:58Z","timestamp":1784653318000},"page":"e308-e311","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Severe Veno-Occlusive Disease in a Child With Wilms Tumor: Acute Management and Subsequent Bridging With Irinotecan Treatment"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-6829","authenticated-orcid":false,"given":"Jessica","family":"Chumsky","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Cellular Therapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahvish","family":"Rahim","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Cellular Therapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6457","authenticated-orcid":false,"given":"Rachel","family":"Offenbacher","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Cellular Therapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-0002","authenticated-orcid":false,"given":"Elizabeth A.","family":"Mullen","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shlomovich","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine, The Children\u2019s Hospital at Montefiore Einstein, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Loeb","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Cellular Therapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weiser","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Cellular Therapy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"R1-20260928","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front Immunol"},{"key":"R2-20260928","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-2008-1071010","article-title":"Hepatic veno-occlusive disease in Wilms\u2019 tumor","volume":"6","author":"Kullendorff","year":"1996","journal-title":"Eur J Pediatr Surg"},{"key":"R3-20260928","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R4-20260928","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0959-8049(01)00097-1","article-title":"Veno-occlusive disease with multi-organ involvement following actinomycin-D","volume":"37","author":"D\u2019Antiga","year":"2001","journal-title":"Eur J Cancer"},{"key":"R5-20260928","doi-asserted-by":"crossref","first-page":"e36883","DOI":"10.1016\/j.heliyon.2024.e36883","article-title":"Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: a systematic review","volume":"10","author":"Fan","year":"2024","journal-title":"Heliyon"},{"key":"R6-20260928","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2017.08.035","article-title":"Consensus report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on supportive care guidelines for management of veno-occlusive disease in children and adolescents, part 3: focus on cardiorespiratory dysfunction, infections, liver dysfunction, and delirium","volume":"24","author":"Ovchinsky","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"R7-20260928","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.22.02555","article-title":"Severe hepatopathy in national Wilms tumor studies 3-5: prevalence, clinical features, and outcomes after reintroduction of chemotherapy","volume":"41","author":"Oosterom","year":"2023","journal-title":"J Clin Oncol"},{"key":"R8-20260928","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pbc.24785","article-title":"Treatment of multiply relapsed Wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab","volume":"61","author":"Venkatramani","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20260928","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.01265","article-title":"Activity of vincristine and irinotecan in diffuse anaplastic Wilms tumor and therapy outcomes of stage II to IV disease: results of the Children\u2019s Oncology Group AREN0321 study","volume":"38","author":"Daw","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R11-20260928","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40265-018-1018-z","article-title":"Hepatic encephalopathy: definition, clinical grading and diagnostic principles","volume":"79","author":"Weissenborn","year":"2019","journal-title":"Drugs"},{"key":"R12-20260928","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/pbc.24658","article-title":"Outcome of patients with Stage II\/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group","volume":"61","author":"Green","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20260928","article-title":"Treatment of newly diagnosed diffuse anaplastic Wilms tumors (DAWT) and relapsed favorable histology Wilms tumors (FHWT): a COG groupwide phase 2 study","author":"Geller","year":"2020","journal-title":"Children\u2019s Oncology Group"},{"key":"R15-20260928","doi-asserted-by":"crossref","first-page":"721564","DOI":"10.3389\/fonc.2021.721564","article-title":"Irinotecan plus doxorubicin hydrochloride liposomes for relapsed or refractory Wilms tumor","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R16-20260928","first-page":"843","article-title":"Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma","volume":"26","author":"Sulis","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R17-20260928","doi-asserted-by":"crossref","first-page":"300060520980877","DOI":"10.1177\/0300060520980877","article-title":"Outcomes of combination treatment with MARS and TIPS for hepatic veno-occlusive disease: a report of 12 cases","volume":"48","author":"Deng","year":"2020","journal-title":"J Int Med Res"},{"key":"R18-20260928","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00467-013-2691-5","article-title":"Molecular absorbent recirculating system therapy (MARS\u00ae) in pediatric acute liver failure: a single center experience","volume":"29","author":"Bourgoin","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"R19-20260928","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1525-1594.2003.02003.x","article-title":"Case report of the first severe acute respiratory syndrome patient in China: successful application of extracorporeal liver support MARS therapy in multiorgan failure possibly induced by severe acute respiratory syndrome","volume":"27","author":"Luo","year":"2003","journal-title":"Artif Organs"},{"key":"R20-20260928","first-page":"e1002","article-title":"Molecular adsorbent recirculating system for acute liver failure in a new pediatric-based extracorporeal liver support program","volume":"5","author":"Baker","year":"2023","journal-title":"Crit Care Explor"},{"key":"R21-20260928","doi-asserted-by":"crossref","first-page":"JCO1800076","DOI":"10.1200\/JCO.18.00076","article-title":"Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor: a report from the Children\u2019s Oncology Group","volume":"36","author":"Mullen","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:10Z","timestamp":1790622010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003253","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"2026-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}